Table 1 Characteristics of subjects [mean ± SD or N (%)] during baseline and follow-up periodsa by status at follow-up (hypertensive, nonhypertensive)
Characteristic | Hypertensive subjects (N = 744) | Nonhypertensive subjects (N = 2847) | P-value hypertensive versus nonhypertensive | |||
|---|---|---|---|---|---|---|
Baseline | Follow-up | Baseline | Follow-up | Baseline | Follow-up | |
Male (%) | 570 (76.61 %) | 1980 (69.55 %) | 0.000 | 0.000 | ||
Female (%) | 174 (23.39 %) | 867 (30.45 %) | ||||
Age (years) | 61.47 ± 11.66 | 63.82 ± 11.63 | 55.61 ± 13.41 | 56.64 ± 13.33 | 0.000 | 0.000 |
BMI (kg/m2) | 24.85 ± 3.04 | 24.76 ± 2.92 | 24.06 ± 3.03 | 24.01 ± 3.00 | 0.000 | 0.000 |
Overweight (BMI = 24–27.9 kg/m2) | 350 (47.0 %) | 346 (46.5 %) | 1115 (40.5 %) | 1130 (39.7 %) | – | – |
Obese (BMI ≥ 28 kg/m2) | 105 (14.1 %) | 96 (12.9 %) | 268 (9.4 %) | 253 (8.9 %) | – | – |
TG (mg/dl) | 148.85 ± 95.69 | 149.73 ± 82.40 | 131.13 ± 95.69 | 134.67 ± 93.05 | 0.000 | 0.000 |
TC (mg/dl) | 188.27 ± 32.47 | 189.82 ± 30.54 | 186.34 ± 32.47 | 186.73 ± 30.54 | 0.165 | 0.023 |
HDL (mg/dl) | 51.80 ± 15.46 | 51.03 ± 14.69 | 53.35 ± 15.46 | 53.35 ± 15.46 | 0.059 | 0.000 |
eGFR (ml/min/1.73 m2) | 86.96 ± 17.03 | 86.62 ± 15.69 | 90.51 ± 18.15 | 91.31 ± 22.62 | 0.000 | 0.000 |
≥60 (ml/min/1.73 m2) | 711 (95.6 %) | 712 (95.7 %) | 2727 (95.8 %) | 2738 (96.2 %) | – | – |
<60 (ml/min/1.73 m2) | 33 (4.4 %) | 32 (4.3 %) | 120 (4.2 %) | 109 (3.8 %) | – | – |
SUA (mg/dl) | 6.26 ± 1.38 | 5.65 ± 1.20 | 5.50 ± 1.33 | 5.47 ± 1.27 | 0.000 | 0.000 |
BUN (mg/dl) | 15.41 ± 3.53 | 15.49 ± 2.97 | 14.54 ± 3.53 | 14.57 ± 3.36 | 0.000 | 0.000 |
SCR (mg/dl) | 0.92 ± 0.21 | 0.91 ± 0.18 | 0.88 ± 0.18 | 0.88 ± 0.17 | 0.000 | 0.000 |
SBP (mmHg) | 140 | 140 | 119.62 ± 10.97 | 119.60 ± 10.46 | 0.000 | 0.000 |
DBP (mmHg) | 90 | 90 | 70.01 ± 8.83 | 69.59 ± 8.41 | 0.000 | 0.000 |
FBG (mg/dl) | 92.44 ± 22.71 | 98.93 ± 21.26 | 92.08 ± 18.02 | 94.42 ± 16.58 | 0.682 | 0.000 |
TP (g/L) | 75.28 ± 4.06 | 74.69 ± 3.51 | 82.38 ± 10.83 | 73.68 ± 3.68 | 0.000 | 0.000 |
GLB (g/L) | 29.66 ± 3.36 | 29.56 ± 3.07 | 28.27 ± 3.42 | 28.15 ± 3.27 | 0.000 | 0.000 |
ALB (g/L) | 45.62 ± 2.61 | 45.12 ± 2.14 | 45.67 ± 2.70 | 45.52 ± 2.51 | 0.641 | 0.000 |
ALT (IU/L) | 28.63 ± 22.08 | 25.25 ± 12.29 | 23.26 ± 17.98 | 22.19 ± 11.90 | 0.000 | 0.000 |
TBIL (mg/dl) | 0.82 ± 0.29 | 0.90 ± 0.29 | 0.82 ± 0.31 | 0.84 ± 0.29 | 0.265 | 0.000 |
DBIL mg/dl) | 0.12 ± 0.07 | 0.17 ± 0.10 | 0.19 ± 0.11 | 0.20 ± 0.09 | 0.000 | 0.000 |
Hypertension incidence (2007–2011) | ||||||
2006 n/incidence (baseline/follow-up) | 0/0.00 % (932/821) | |||||
2007 n/incidence (baseline/follow-up) | 155/9.15 % (1694/1567) | |||||
2008 n/incidence (baseline/follow-up) | 191/11.27 % (1695/1636) | |||||
2009 n/incidence (baseline/follow-up) | 157/8.92 % (1761/1683) | |||||
2010 n/incidence (baseline/follow-up) | 122/6.89 % (1770/1615) | |||||
2011 n/incidence (baseline/follow-up) | 119/5.73 % (2077/2077) | |||||